Clinical Trial Update: Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated dasatinib in lymphoid blast phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Philadelphia Chromosome-positive
• Chronic Myeloid Leukemia

Drugs mentioned

• Dasatinib (Sprycel) (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive | Phase 2 | Status: COMPLETED